Clinical trial
Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer
NCT00089999 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00089999 |
|---|---|
| Title | Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer |
| Official title | A Phase II, Open-Label, Randomized, Parallel-Group Multicenter Trial Comparing Two Schedules of GW572016 as First-Line Monotherapy in Patients With Advanced or Metastatic Breast Cancer |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms, Breast |
| Intervention type | Drug |
| Interventions | Lapatinib |
| Enrollment | 138 |
| Start date | Jun 1, 2004 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Aug 23, 2004 |
| Last update posted | Feb 28, 2017 |
| Countries | Chile, Hong Kong, India, Malaysia, Mexico, Pakistan, Peru, Poland, Singapore, Taiwan, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: